American Oncology Network | Genesis Cancer and Blood Institute

Research site

(Unclaimed)

Location

133 Harmony Park Cir, Hot Springs, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Sacituzumab

Domvanalimab

Gemcitabine

Abiraterone

-Paclitaxel

SBP-101

Pembrolizumab

LY2835219

Abemaciclib

Parent organization

This site is a part of American Oncology Network

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting

Cytochrome P-450

Antineoplastic Agents, Hormonal

Drug: Placebo for Abemaciclib

Drug: Abemaciclib

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or with...

Enrolling

Pancreatic Cancer Metastatic

Pancreatic Cancer Stage IV

Drug: Gemcitabine

Drug: Nab-paclitaxel

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling

Triple Negative Breast Cancer

PD-L1 Positive

Drug: Pembrolizumab

Drug: Carboplatin

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms